Abstract: Methods are disclosed for diagnosing chemotherapeutic drug resistance in neoplastic cells by detecting an increase in the expression of calumenin in such neoplastic cells as compared to the level of expression of calumenin protein in a non-MDR neoplastic cell. In addition, disclosed are methods for treating neoplastic cells, including reversing or preventing chemotherapeutic drug resistance, by increasing the sensitivity of the neoplastic cells to a chemotherapeutic drug.

Abstract: Disclosed are methods for treating neoplastic cells, including reversing or preventing chemotherapeutic drug resistance, by increasing the sensitivity of the neoplastic cells to a chemotherapeutic drug. In addition, methods are further disclosed for diagnosing chemotherapeutic drug resistance in neoplastic cells by detecting an increase in the expression of prohibitin in such neoplastic cells as compared to the level of expression of prohibitin protein in a non-MDR neoplastic cell.

Abstract: Disclosed are methods for detecting a neoplasm and/or chemotherapeutic drug resistance or angiogenic potential in neoplastic cells by detecting an increase in the expression of ?-enolase in such cells, or in the case of metastatic potential on the surface of such cells, as compared to the level of expression of ?-enolase protein in a normal or non-MDR neoplastic cell or on the surface of a non-metastatic neoplastic cell. In addition, methods and a composition are disclosed for increasing the sensitivity of a neoplasm to a chemotherapeutic drug treatment regime, for inhibiting angiogenesis and metastatic potential in chemotherapeutic drug resistant or neoplastic cells, and for inducing apoptosis in chemotherapeutic drug resistant or neoplastic cells.

Abstract: Disclosed are methods for detecting adriamycin resistance in a test neoplastic cell from a non-hematological cancer. The methods include detecting a level of p16 expression in the test neoplastic cell of a given origin or cell type, and comparing the level of p16 expression detected in the test neoplastic cell to the level of p16 expression in a nonresistant neoplastic cell of the same origin or cell type, wherein the test neoplastic cell is adriamycin resistant if the level of p16 expression is greater than the level of p16 expression in the nonresistant neoplastic cell of the same origin or cell type. Also disclosed are therapeutic compositions comprising an agent that inhibits p16 and a pharmaceutically acceptable carrier.